Asceneuron
Latest round
- Series C
Last raised
- Jul 2024
Total raised
- $137M
Investors
- 9
About Asceneuron
Based in Lausanne, Switzerland, and co-founded by Dirk Beher in 2012, as a spin-off from Merck Serono’s Alzheimer’s drug discovery portfolio, Asceneuron SA operates as a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders like Alzheimer's, Parkinson's disease, and orphan tauopathies. The company focuses on creating oral therapies to halt abnormal protein aggregation, a common feature in neurodegenerative diseases. Asceneuron’s pipeline includes two leading O-GlcNAcase inhibitors, ASN51 and ASN90. Both have completed Phase 1 clinical studies, demonstrating significant brain penetration and inhibition of protein aggregation. ASN51 is poised to enter Phase 2 trials for Alzheimer’s disease in late 2024. ASN90 is licensed to Ferrer for treating progressive supranuclear palsy (PSP) and is also being explored for additional indications. Additionally the firm also engages in research publications and some of them include IP-LC-MSMS Enables Identification of Three Tau O-GlcNAcylation Sites as O-GlcNAcase Inhibition Pharmacodynamic Readout in Transgenic Mice Overexpressing Human Tau, O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and a-Synuclein Proteinopathies, etc.
Who invested in Asceneuron
9 investors across 3 rounds
See all investors in Asceneuron
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Asceneuron
Who invested in Asceneuron?
Asceneuron has 9 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Asceneuron raised?
Asceneuron has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Asceneuron last raise money?
Asceneuron's most recent round on record is a Series C, in Jul 2024.
What does Asceneuron do?
Based in Lausanne, Switzerland, and co-founded by Dirk Beher in 2012, as a spin-off from Merck Serono’s Alzheimer’s drug discovery portfolio, Asceneuron SA operates as a biotechnology company dedicated to discovering and developing therapeutics for neurodegenerative disorders like Alzheimer's, Parkinson's disease, and orphan tauopathies.
Where is Asceneuron headquartered?
Asceneuron is headquartered in Lausanne, Switzerland.
Which VCs invest in companies like Asceneuron?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Asceneuron's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Asceneuron? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.